Jordana Fein, MD, MS, presented 64-week QUASAR data showing aflibercept 8 mg sustained visual acuity gains with up to 3 fewer injections than aflibercept 2 mg in macular edema following RVO.
Real-world SPECTRUM data shows strong fluid resolution and vision gains by week 12, with low adverse events and no retinal vasculitis. Welcome back to another Ophthalmology Times Europe Rapid Readout.
Real-world Spectrum data show aflibercept 8 mg boosts early vision and retinal anatomy in wet AMD, including switch patients. Welcome back to another Ophthalmology Times Europe Rapid Readout. In this ...
Not every patient with geographic atrophy (GA) fits neatly into the criteria used in the pivotal clinical trials that led to the FDA approval of pegcetacoplan and avacincaptad pegol. That gap shaped a ...
Three cases illustrate treatment switches and extension intervals across retinal vein occlusion, age-related macular degeneration, and diabetic retinopathy.
For Caroline R. Baumal, MD, a path from academic retina through industry leadership has brought her full circle—back to the ...
The European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended approval of Roche’s ...
For a historically underserved and often underrecognized population, the encapsulated cell technology platform represents a rare treatment option in a disease with no prior therapy, but it also ...
The phase 2 EVIAN study (Early Vitrectomy and Intravitreal Antibiotics for Post-Operative Exogenous Endophthalmitis) found ...
OPTIC data showed a single injection of Ixo-vec gene therapy cut annualized anti-VEGF injections 87%, with sustained ...
The approval establishes LYTENAVA as the first and only FDA-approved ophthalmic formulation of bevacizumab for the treatment ...
An AI platform that screens patient charts for clinical trial eligibility increased randomization by 37.5% and cut screen ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results